Allergic Bronchopulmonary Aspergillosis Clinical Trial
— MIRAGEOfficial title:
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the visualization of pulmonary Aspergillus infection. The incidence of fungal infections is on the rise and are associated with significant mortality. Diagnosis pulmonary aspergillosis can be can be challenging, often requiring invasive tests such as bronchoscopy and lung tissue biopsies. Molecular imaging, specifically using radiolabeled siderophores like [68Ga]Ga-DFO-B, offers a non-invasive and location-specific approach to visualize and evaluate infections. Siderophores, critical for pathogenic microbes like Aspergillus fumigatus, play a role in iron acquisition. Preclinical studies with radiolabeled deferoxamine (DFO-B) demonstrated distinct accumulation at infection sites. Additionally, [68Ga]Ga-DFO-B PET/CT may differentiate between Aspergillus infection and cancer, making it a promising non-invasive diagnostic tool for pulmonary aspergillosis.
Status | Not yet recruiting |
Enrollment | 10 |
Est. completion date | March 1, 2025 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. The patient is at least 18 years old on the day of inclusion. 2. The patient has suspected chronic pulmonary aspergillosis or ABPA. 3. There is no significant interference with standard care and follow-up. Exclusion Criteria: 1. The patient is pregnant or planning on becoming pregnant. 2. The patient has severe kidney dysfunction with eGFR < 30 ml/min/kg and/or receives dialysis. 3. The patient has (chronic) iron overload. 4. The patient has been receiving antifungal treatment for more than 48 hours prior to the study day. 5. The patient is not able to lie still in the scanner. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Radboud University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Standardized uptake values (SUV) of [68Ga]Ga-DFO-B | Measurement of the amount of radiotracer uptake ([68Ga]Ga-DFO-B) in suspected Aspergillus lesions in patients with pulmonary aspergillosis. | PET/CT will be performed 60 minutes after intravenous injection of [68Ga]Ga-DFO-B | |
Primary | Target-to-background ratios of [68Ga]Ga-DFO-B | Ratio of the signal intensity or uptake in suspected Aspergillus lesions (target) to the background signal intensity in the surrounding normal tissues in patients with pulmonary aspergillosis. | PET/CT will be performed 60 minutes after intravenous injection of [68Ga]Ga-DFO-B |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01222273 -
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
|
N/A | |
Completed |
NCT04442269 -
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
|
Phase 2 | |
Terminated |
NCT00787917 -
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
|
Phase 4 | |
Completed |
NCT02273661 -
Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).
|
Phase 2 | |
Not yet recruiting |
NCT05129033 -
A Prospective Study on Optimizing Treatment for ABPA
|
N/A | |
Completed |
NCT02440009 -
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
Completed |
NCT01857479 -
A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
Completed |
NCT00585364 -
Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA
|
N/A | |
Completed |
NCT01621321 -
Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05444946 -
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
|
N/A | |
Terminated |
NCT03960606 -
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
|
Phase 2 | |
Active, not recruiting |
NCT04227483 -
Deflazacort vs. Prednisolone in Acute-stage ABPA
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05903612 -
Allergic Bronchopulmonary Aspergillosis Prescreening Study
|
||
Completed |
NCT04229303 -
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
|
Phase 1 | |
Completed |
NCT04476758 -
Immune Profiles in CF Fungal Infection
|
||
Withdrawn |
NCT04108962 -
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
|
Phase 4 | |
Recruiting |
NCT06174922 -
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
|
Phase 3 | |
Completed |
NCT01321827 -
Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
Completed |
NCT00974766 -
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
|
Phase 2/Phase 3 | |
Completed |
NCT03059992 -
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
|
Phase 3 |